199 related articles for article (PubMed ID: 32133282)
21. Development and Validation of a Radiomic Nomogram for Predicting the Prognosis of Kidney Renal Clear Cell Carcinoma.
Gao R; Qin H; Lin P; Ma C; Li C; Wen R; Huang J; Wan D; Wen D; Liang Y; Huang J; Li X; Wang X; Chen G; He Y; Yang H
Front Oncol; 2021; 11():613668. PubMed ID: 34295804
[TBL] [Abstract][Full Text] [Related]
22. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.
Song J; Shi J; Dong D; Fang M; Zhong W; Wang K; Wu N; Huang Y; Liu Z; Cheng Y; Gan Y; Zhou Y; Zhou P; Chen B; Liang C; Liu Z; Li W; Tian J
Clin Cancer Res; 2018 Aug; 24(15):3583-3592. PubMed ID: 29563137
[No Abstract] [Full Text] [Related]
23. A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment.
Jiang Y; Wang Y; Fu S; Chen T; Zhou Y; Zhang X; Chen C; He LN; Du W; Li H; Lin Z; Zhao Y; Yang Y; Zhao H; Fang W; Huang Y; Hong S; Zhang L
Thorac Cancer; 2022 Jun; 13(11):1558-1569. PubMed ID: 35437945
[TBL] [Abstract][Full Text] [Related]
24. Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
Yang X; Fang C; Li C; Gong M; Yi X; Lin H; Li K; Yu X
Front Oncol; 2022; 12():904983. PubMed ID: 35875167
[TBL] [Abstract][Full Text] [Related]
25. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
26. Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature.
Zhang X; Lu B; Yang X; Lan D; Lin S; Zhou Z; Li K; Deng D; Peng P; Zeng Z; Long L
Eur Radiol; 2023 Feb; 33(2):825-835. PubMed ID: 36166088
[TBL] [Abstract][Full Text] [Related]
27. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
[TBL] [Abstract][Full Text] [Related]
28. Application of radiomics signature captured from pretreatment thoracic CT to predict brain metastases in stage III/IV ALK-positive non-small cell lung cancer patients.
Xu X; Huang L; Chen J; Wen J; Liu D; Cao J; Wang J; Fan M
J Thorac Dis; 2019 Nov; 11(11):4516-4528. PubMed ID: 31903240
[TBL] [Abstract][Full Text] [Related]
29. A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.
Zheng X; Shao J; Zhou L; Wang L; Ge Y; Wang G; Feng F
Ther Innov Regul Sci; 2022 Jan; 56(1):155-167. PubMed ID: 34699046
[TBL] [Abstract][Full Text] [Related]
30. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
31. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.
Kirienko M; Cozzi L; Antunovic L; Lozza L; Fogliata A; Voulaz E; Rossi A; Chiti A; Sollini M
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):207-217. PubMed ID: 28944403
[TBL] [Abstract][Full Text] [Related]
32. Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients.
Song L; Zhu Z; Mao L; Li X; Han W; Du H; Wu H; Song W; Jin Z
Front Oncol; 2020; 10():369. PubMed ID: 32266148
[No Abstract] [Full Text] [Related]
33. Pretherapy investigations using highly robust visualized biomarkers from CT imaging by multiple machine-learning techniques toward its prognosis prediction for ALK-inhibitor therapy in NSCLC: a feasibility study.
Sun J; Li F; Yang J; Lin C; Zhou X; Liu N; Zhang B; Song G; Wang W; Huang C; Song Z; Shi L
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7341-7353. PubMed ID: 36928998
[TBL] [Abstract][Full Text] [Related]
34. CT-derived radiomic analysis for predicting the survival rate of patients with non-small cell lung cancer receiving radiotherapy.
Zhang N; Zhang X; Li J; Ren J; Li L; Dong W; Liu Y
Phys Med; 2023 Mar; 107():102546. PubMed ID: 36796178
[TBL] [Abstract][Full Text] [Related]
35. Value of pre-therapy
Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
[TBL] [Abstract][Full Text] [Related]
36. Preoperative computed tomography-guided disease-free survival prediction in gastric cancer: a multicenter radiomics study.
Wang S; Feng C; Dong D; Li H; Zhou J; Ye Y; Liu Z; Tian J; Wang Y
Med Phys; 2020 Oct; 47(10):4862-4871. PubMed ID: 32592224
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma.
Song J; Tian J; Zhang L; Qu X; Qian W; Zheng B; Zhang L; Zhao J; Niu M; Zhou M; Cui L; Liu Y; Zhao M
Eur Radiol; 2019 May; 29(5):2388-2398. PubMed ID: 30643941
[TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
[TBL] [Abstract][Full Text] [Related]
39. Predictive Power of a Radiomic Signature Based on
Li X; Yin G; Zhang Y; Dai D; Liu J; Chen P; Zhu L; Ma W; Xu W
Front Oncol; 2019; 9():1062. PubMed ID: 31681597
[TBL] [Abstract][Full Text] [Related]
40. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
